APRIL 9, 2019
Glytec Receives Another Patent Allowance for Therapy Advisor®
The company is expanding its software-as-a-medical-device platform to support the optimization of ALL diabetes medications.
Waltham, MA — The United States Patent and Trademark Office has granted Glytec another patent allowance for systems and methods related to a product registered under the brand name, Therapy Advisor®. Currently under development, the new product will extend the company’s core competencies beyond insulin optimization to include oral, inhaled and non-insulin injectable diabetes medications.
The patent allowance depicts the following key systems and methods: [highly abridged and consolidated]
Glytec has grown its intellectual property portfolio to more than two dozen issued and allowed patents. “Developing cutting-edge innovations is a hallmark of Glytec’s DNA, and Therapy Advisor® is the latest example of that,” says Robby Booth, Senior Vice President Research & Development. “This newest allowance is one of many more to come, both domestic and international. We’ll be issuing additional announcements in the near future.”
About Glytec
Founded in 2006, Glytec is the pioneer of digital therapeutics, improving the lives of people with diabetes by making insulin a more effective and accessible option for millions unable to achieve their treatment goals. The company’s patented eGlycemic Management System® is the only FDA-cleared software-as-a-medical-device (SaMD) platform to enable the mass personalization of insulin across the continuum of care: inpatient, outpatient and virtual settings alike. Glytec offers several comprehensive programs combining evidence-based decision support technologies with expert professional services proven to aid providers in achieving best practices and standardization while reducing hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.